Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Donald Trump announces major change to "frivolous grants" Trump’s tariffs are now in place. Alcohol, a cup of joe and Toyotas are about to cost a whole lot more Workers Reveal What You Should ...

Embecta Corp. achieves record Q3 2025 revenue, raises EPS guidance, and highlights GLP-1 partnerships, debt reduction, and free cash flow growth.

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

With salty snack dollars slumping, leveraging ‘sweet spots’ and navigating the ‘snackscape’ could help regain share ...

The brand known for its drink mix-ins is launching its first protein shake, while a cocktail mix maker is bringing Bloody ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 global studies. Researchers found that although these medications, including ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

In its first public earnings call after its initial public offering in June, virtual chronic disease provider Omada Health reported $61 million in revenue, up 49% year over year. | The virtual chronic ...